

Special Issue

Targeting the Sphingolipid Metabolic Pathway: Promotion from Benchwarmer to the Starting Lineup—a Themed Issue in Memory of Drs. Lina Obeid and Mark Kester

Message from the Guest Editor

We have lost two dear friends, colleagues, and mentors in the past few years. The passing of Drs. Lina Obeid and Mark Kester remind us all to cherish each moment with our families, friends, and colleagues. In their honor, I invite you to submit a manuscript to this Special Issue of *Cancers* entitled “Targeting the Sphingolipid Metabolic Pathway: Promotion from Benchwarmer to the Starting Lineup”. This Special Issue is designed to assemble important studies in the area of targeted therapies directed toward sphingolipid metabolizing enzymes as anticancer strategies, either as standalone therapies, novel combinatorial therapies, or as adjuvants to existing therapies. I am sure that I am not alone in my feeling that it was an honor to know both Lina and Mark. I am pleased to invite you to submit an article to this Special Issue as an acknowledgment of their dedication and leadership.

Guest Editor

Dr. Jeremy A. Hengst

Department of Pharmacology, Pennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033, USA

Deadline for manuscript submissions

closed (25 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/158765

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)